Same reason as other strategies/tactics are not explained to the market. They don't want regulators etc reading their releases as that could make negotiating favourable regulatory outcomes more difficult. Its not really a good strategy anymore if everyone knows about it...
It's really up to the investor to see that this is a very well run company, and to back the management team who clearly know what they're doing.
- Forums
- ASX - By Stock
- CUV
- Ann: SCENESSE European Orphan Drug Designation for VP
Ann: SCENESSE European Orphan Drug Designation for VP, page-13
-
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CUV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$14.92 |
Change
-0.030(0.20%) |
Mkt cap ! $747.1M |
Open | High | Low | Value | Volume |
$14.91 | $15.19 | $14.71 | $936.9K | 62.45K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 167 | $14.92 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.00 | 57 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 167 | 14.920 |
1 | 500 | 14.900 |
1 | 168 | 14.890 |
1 | 168 | 14.860 |
1 | 168 | 14.830 |
Price($) | Vol. | No. |
---|---|---|
15.000 | 57 | 1 |
15.130 | 168 | 1 |
15.150 | 519 | 1 |
15.160 | 168 | 1 |
15.170 | 659 | 1 |
Last trade - 16.10pm 01/08/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |